Daklizumaʙ
When ATH:
L04AC01
Characteristic.
Рекомбинантные гуманизированные антитела IgG1 (anti-Tas).
Pharmacological action.
Immunosuppressive.
Application.
Prevention of acute rejection kidney allograft (as part of combination immunosuppressive therapy with cyclosporin and corticosteroids).
Contraindications.
Hypersensitivity.
Restrictions apply.
Advanced age (safety and efficacy in people over 65 years to be determined due to the limited number of direct, performed for patients in this age group).
Pregnancy and breast-feeding.
Maybe, if the effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.
Side effects.
From the nervous system and sensory organs: ≥5% — головная боль, dizziness, insomnia, tremor; 2–5% — покалывание и судороги в ногах, depression, alarm, blurred vision.
Cardio-vascular system and blood (hematopoiesis, hemostasis): ≥5% — артериальная гипертензия или гипотензия, tachycardia, bleeding or thrombosis.
From the respiratory system: ≥5% — кашель, breathlessness, pulmonary edema; 2–5% — ателектаз, congestion and pleural effusion, crepitation, pharyngitis, rhinitis, gipoksiya.
From the digestive tract: ≥5% — тошнота, vomiting, constipation or diarrhea, dyspepsia, abdominal pain, epigastric pain; 2–5% — метеоризм, gastritis, hemorrhoids.
With the genitourinary system: ≥5% — дизурия, oligurija, swelling, renal tubular necrosis, lymphocele; 2–5% — поражение почек, gidronefroz, renal failure, fluid retention, dehydration, hematuria, urinary retention.
On the part of the musculoskeletal system: ≥5% — боль в костях и мышцах, lower back pain; 2–5% — боль в суставах.
For the skin: ≥5% — ухудшение регенерации кожи, acne; 2–5% — зуд, girsutizm, rash, Sweating, injection site reactions.
Other: ≥5% — боль в грудной клетке, fever, weakness; 2–5%: giperglikemiâ, chills, anaphylactoid reactions.
Cooperation.
Pharmaceutically compatible with other solutions. There were no reports of interaction with immunoglobulin antilymphocytic, cyclosporine, kortikosteroidami, mycophenolate mofetil, azathioprine, ganciclovir, acyclovir, etc..
Overdose.
Symptoms of overdose have been identified.
Dosing and Administration.
B /, slowly (during 15 m), a peripheral or central vein. The recommended dose - 1 mg / kg body weight (pre-diluted concentrate 0,9% sodium chloride). Первое введение — за 24 ч до трансплантации, second and subsequent doses (всего — 5 doses) administered at intervals of 14 days. The timing of administration of subsequent doses should not differ from the scheduled more than one day in both directions.
Precautions.
Women of childbearing age should use adequate contraceptive measures during treatment and during 4 months after the end.
Cautions.
It is used only under the supervision of qualified medical personnel.
